SCYX: Multiplikator Forward P/S SCYNEXIS

Logo perusahaan publik SCYNEXIS Inc (SCYX)

Amidst fierce competition with global pharma behemoths, the forward P/S history of SCYNEXIS, Inc. (SCYX) demonstrates resilience. The patent-protected triterpenoid platform featuring Brexafemme creates barriers for competitors, while steady cash flow from the core product precludes a sharp revenue decline. Consequently, the metric remains around 1.80, confirming the market's willingness to pay for the issuer's future earnings.

SCYX SCYNEXIS Inc: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 13.11.2026

Rincian analitis perusahaan SCYNEXIS, Inc.

- rega saham lan target rega konsensus:
Kutipan saham SCYNEXIS|SCYX - Rega prakiraan analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar SCYX|SCYX - Rega Tumbas Perusahaan
- statistik nilai buku emiten:
Aset Bersih saben Siji Saham SCYNEXIS|SCYX - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku scynexis.com|SCYX - Total Aset Bisnis
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas SCYNEXIS, Inc.|SCYX - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas SCYNEXIS|SCYX - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku SCYX|SCYX - Kewajiban jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan SCYNEXIS|Likuiditas cepet scynexis.com
- data bathi bisnis lan rasio investasi:
SCYX - Bathi perusahaan|Proyeksi bathi mangsa ngarep SCYNEXIS, Inc.|SCYX - Kapitalisasi marang bathi|Prakiraan rega marang bathi SCYNEXIS|SCYX - Rasio P/E diaturake wutah|Pangali EV/EBITDA SCYX|SCYX - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan SCYNEXIS|SCYX - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan scynexis.com|SCYX - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep SCYNEXIS, Inc.
- rincian pendapatan lan dodolan:
SCYX - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan SCYNEXIS|SCYX - Rasio kapitalisasi marang pendapatan|Multiplikator Forward P/S SCYX
Analisis komprehensif perusahaan:Scynexis SCYX
Produk asli SCYNEXIS

Professional managers utilize fundamental filters to assess the market value of future cash flows relative to expected sales. The trend of the forward price-to-sales ratio reflects a reassessment of risks by investors, which is critical for SCYNEXIS, Inc. (SCYX) during the stabilization of ibrexafungerp quality, as any deviations in the chart signal a shift in market sentiment regarding the drug's successful return to circulation.

Pesaing SCYNEXIS, Inc. (SCYX)

Summit Therapeutics Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake MRNA (Moderna Inc)|Vaxcyte Corp - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Tarsus Corp TARS|CorMedix Inc. (CRMD) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep serestherapeutics.com (MCRB)|Rasio rega marang prakiraan pendapatan Spero Therapeutics, Inc.|Kapitalisasi marang prakiraan pendapatan ANTX (AN2 Bio)|Rasio rega marang prakiraan pendapatan PolyPid Ltd. (PYPD)|Rasio kapitalisasi marang dodolan sing dikarepake YS Biopharma Co., Ltd.|Rasio rega marang prakiraan pendapatan Iterum Therapeutics ITRM|Rasio kapitalisasi marang dodolan sing dikarepake BiomX Inc (PHGE)|BioPharma Bio - Multiplikator Forward P/S|60 Degrees Pharmaceuticals (SXTP) - Multiplikator forward rega marang pendapatan|OGEN (Oragenics) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep OpGen Corporation (OPGN)